ionHP Biodecontamination Technology for Aseptic Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ionHP Biodecontamination Technology for Aseptic Systems



The ionHP biodecontamination system by Telstar is used in aseptic enclosures to resolve difficulties associated with hydrogen peroxide biodecontamination processes. The ionHP technology increases the efficacy of the decontamination process and reduces degradation of construction materials by requiring a low concentration of hydrogen peroxide. In addition, the reduced bio-decontamination cycle times are possible since the process efficiency is not affected by temperature and humidity; there is no need to pre-condition the chamber prior to the hydrogen peroxide injection, according to the company.

ionHP can be used in open air and, once ionized, acts like a gas as opposed to a vapor, which offers operational, commercial, and environmental benefits. According to the company, this gives the ionHP a shorter decontamination process time and it does not require special atmospheric conditions, which eliminates the need for the air conditioning units required with traditional systems, reducing equipment cost. The ionHP also uses a base concentration of 7.5% volume, while traditional hydrogen peroxide systems use 30-35%.

This new system is also is more effective due to the positively charged droplets being attracted to the negatively charged surface areas and the ionHP does not leave behind any residue, reducing costs by shortening cleaning activities, the company reports.

Source: Telstar

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here